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INTRODUCTION 
The majority of active pharmaceutical ingredients (APIs) are small-molecule organic crystals.1,2 
Crystallization is an essential step in their production, wherein the form (i.e. polymorph), crystal 
morphology, and crystal size impacts processing as well as other important physicochemical properties, 
including solubility and dissolution rate.3-5 Dissolution is the first step in drug absorption from the solid 
form, and it plays a critical role in drug bioavailability.6,7 Crystals are bounded by faces that are 
truncations of the three-dimensional lattice along specific crystallographic directions. As such, 
crystallographically unique faces are expected to exhibit different growth and dissolution behavior. 
Growth morphologies and kinetics of well-defined crystal faces have been explored using methods such 
as in situ scanning probe and interferometric microscopies,8-13 often providing more insightful and 
accurate measurements of crystal growth than statistical sampling of bulk crystal morphologies.14 
Likewise, measurements of the dissolution kinetics of crystal suspensions that provide average rates of a 
population of crystals are common,15-17 but measurements of dissolution of individual crystal faces of 
single crystals are rare. Mass transport conditions in such systems depend on several parameters that are 
not easily quantified, including type and speed of the stirrer, vessel and baffle geometry,18,19 solution 
density and viscosity, diffusion, crystal morphology, and the quantity and size distribution of the solid 
particles.18,20 Mass transport typically is not well defined, to the extent that deducing the kinetic regime 
can be difficult. Ideally, experimental studies should be configured to allow quantitative local mass 
transport, from which local undersaturation at the solid/liquid interface and the relationship between 
surface structure and reactivity can be obtained. Flow cell techniques overcome some of the 
limitations,21,22 but typically these are limited to large macroscopic sample areas and particular crystal 
faces.  
These approaches often are not ideal for the dissymmetric character of organic crystal surfaces, which 
typically are decorated with various crystallographically unique faces, edges, corners and defects that 
contribute differently to the dissolution process (mechanism and rate). In this respect, near-field 
microscopies are proving valuable for the study of the dissolution of individual crystals, including atomic 
force microscopy (AFM),23-26 optical microscopy,27,28 and scanning electrochemical microscopy 
(SECM).29 Rapid interfacial dissolution kinetics of crystals have been determined by SECM30 and 
scanning electrochemical cell microscopy (SECCM).31 In situ interferometry32 can be useful for 
determining concentration gradients at crystal/solution interfaces by monitoring changes in the refractive 
index of the solution, although the minimum detectable concentration difference depends on the minimum 
fringe shift (ca. 10% of the total concentration change in solution)33 and interferometric data tend to 
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represent the average across the studied area. As such, they usually are not suitable for high resolution 
measurements of heterogeneous reactivity or concentration gradients.  
New approaches for assessing dissolution kinetics are essential for the optimization of drug formulations, 
particular methodologies that permit facile and quantitative characterization of dissolution at a 
microscopic level that will fill knowledge gaps at the molecular level. Herein we describe a 
comprehensive approach to real-time characterization of the dissolution of individual faces of single 
crystals using optical microscopy, scanning ion-conductance microscopy (SICM) and finite element 
method modeling. SICM is a powerful non-contact method that makes use of a nanopipette for high 
resolution topographical imaging,34-36 with the potential to map the dissolution behavior of individual 
topographical features on crystal surfaces. Collectively, these enable determination of concentration 
gradients, interfacial concentrations, and separation of kinetic and mass transport limiting regimes. This 
approach is demonstrated here for the API furosemide (Scheme 1), a loop diuretic drug marketed under 
the brand name Lasix.37 Furosemide is a weak acid, classified as a BCS Class IV drug because of its low 
permeability and poor solubility.38 Consequently, the bioavailability of furosemide from oral dosage is 
low (60%) and the rate and extent of absorption varies between and within individuals.39 It is reasonable 
to suggest that understanding the dissolution kinetics of furosemide crystals at the microscopic level 
could lead to strategies for improving its bioavailability and its optimum solid-state form.3,40-43 
 
 
Scheme 1. The molecular structure of furosemide 
 
EXPERIMENTAL 
Samples and solutions. Furosemide was purchased from Sigma-Aldrich (>98%, St. Louis, MO) and used 
as obtained without further purification. Crystals of furosemide were prepared by mixing 0.5 mL of a 10 
mM solution of furosemide in ethanol (Sigma-Aldrich, >99.5%) with 3.5 mL deionized (DI) water 
produced by Purite Select HP with resistivity 18.2 MΩ cm (25 °C) to create a supersaturated solution. 
The mixture was added by pipette to a 47 mm diameter circular glass microscope slide (Thermo 
Scientific, Inc., Waltham, MA) previously mounted into a 47 mm diameter Petri dish (Willco Wells, 
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Netherlands) with a Plexiglas rim, covered, and allowed to stand at room temperature for 15 minutes. The 
supernatant solution was then removed to reveal small raft-shaped crystals of furosemide, typically < 60 
µm long, attached to the glass slide, which was then rinsed with water and dried with a nitrogen stream. 
All dissolution studies were performed at 25 °C and pH 6.5 in 50 mM KCl (Sigma-Aldrich, AR grade) in 
ultrapure water. Solution pH was measured with a pH meter (Metler Toledo, Switzerland)). 
X-ray characterization. Single crystal X-ray diffraction analysis of furosemide was performed using a 
suitably large crystal of furosemide (>100 μm) that was mounted on a Mitegen loop with silicon oil and 
placed on an Oxford Diffraction Xcalibur Gemini diffractometer equipped with a Ruby CCD area 
detector. The crystal temperature was maintained at 150(2) K during data collection. The crystal structure 
was solved using Olex244 with the ShelXS-201345 structure solution program using Direct Methods and 
refined with the XL refinement package using Least Squares minimization. Powder X-ray diffraction 
measurements were performed using a Panalytical X'Pert Pro MRD equipped with a hybrid 
monochromator for CuKα1 radiation ( = 1.541 Å). The glass slide on which the furosemide crystals were 
grown was mounted on the sample holder. A Pixcel detector was used in scanning mode over the range 5° 
< 2 < 30°, stepping 0.025° over a period of 45 minutes. 
Morphology prediction. To identify the exposed crystal faces, the furosemide crystal morphology was 
calculated based on the growth morphology method using the Morphology module in Materials Studio 
(Materials Studio 8.0.100.21, Accelrys, San Diego, CA). The growth morphology method takes into 
account the energetics of the system and requires the selection of an appropriate forcefield. The geometry 
of the furosemide unit cell obtained from single crystal CCD X-ray diffraction experiments was optimized 
using the COMPASS, consistent-valence forcefield (cvff), and Dreiding forcefields and the optimized 
unit cell with lowest lattice energy and lattice parameters best matching the experimental unit cell was 
selected for morphology predictions. Geometry optimizations were conducted using the Forcite molecular 
mechanics tool. The Quasi-Newtown algorithm was used with a convergence tolerance of 2.0  10-5 
kcal/mol for the energy, 0.001 kcal/mol/Å for the force, and 1.0  10-5 Å for the displacement. The Ewald 
summation method was chosen for the evaluation of van der Waals and electrostatic terms to an accuracy 
of 0.0001 kcal/mol with a buffer width of 0.5 Å. Forcefield-assigned partial charges were used with the 
COMPASS and cvff forcefields and the QEq method was used to calculate and assign partial charges with 
the Dreiding forcefield. The furosemide unit cell optimized with COMPASS was used for the 
morphology predictions, conducted with a minimum interplanar distance dhkl of 1.300 Å and a maximum 
Miller Index value (hkl) of (333). The maximum number of faces was limited to 200.  
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Scanning ion-conductance microscopy (SICM). Dissolution investigations were performed by 
combining optical microscopy and SICM by mounting an SICM system on an inverted optical 
microscope (Axiovert 40 CFL, Zeiss, Germany). The optical microscope was equipped with an LED light 
source to reduce sample heating and a video camera (B700, PixeLINK) to assist the selection and 
monitoring of the crystal. SICM probes (ca. 100 nm diameter) were fabricated from borosilicate glass 
capillaries (1.2 mm o.d., 0.69 mm i.d., Harvard Apparatus, Holliston, MA) using a laser puller (P-2000, 
Sutter Instruments, Novato, CA) and optimized pulling parameters (Line 1: Heat 350, Fil 3, Vel 30, Del 
220, Line 2: Heat 350, Fil 3, Vel 40, Del 180, Pul 120). The nanopipettes were filled with the same 
electrolyte solution (50 mM KCl) as the aforementioned solution used for dissolution studies. An 
Ag/AgCl quasi-reference counter electrode (QRCE) was inserted into the nanopipette and another was 
submerged in the petri dish bulk solution. The nanopipettes were mounted on a 38 μm – travel range 
single axis (Z) piezoelectric positioner (P-753-3CD, PhysikInstrumente, Germany) to control the height of 
the probe and oriented normal to the surface of interest, as previously described.46 The petri dish 
containing the furosemide crystals was mounted on a two-axis (XY) piezoelectric positioner system 
(Nano-BioS300, Mad City Labs Inc., Madison, WI) for lateral positioning. The SICM was operated in 
bias modulated (BM) mode,47 in which there was zero net bias between the two QRCEs. A lock-in 
amplifier (SR830, Stanford Research Systems, Sunnyvale, CA) was used to generate an oscillating bias 
(38 mV amplitude, 357 Hz frequency) applied to the bulk QRCE, and the resulting current was measured 
at the QRCE in the nanopipette using a custom-built wideband current-to-voltage converter. The 
instrument was controlled and data collected with a programmed FPGA card (7852R, National 
Instruments, Austin, TX) using LabVIEW (2013, National Instruments, Austin TX). 
The experimental configuration for optical and SICM dissolution measurements is illustrated in Figure 1. 
Furosemide crystals, typically with the longest dimension ranging from 30 - 60 μm and various length-
width-height ratios, were selected. Some crystals were removed to create separations greater than 40 
times their largest dimension to ensure high undersaturation (sink conditions) and avoid overlap of 
diffusion profiles among neighboring crystals. Following addition of 4 mL of a 50 mM aqueous solution 
of KCl to the Petri dish, time-lapse sequence of optical images (400 magnification, every 30 s) and line 
traces along the crystal in an SICM hopping mode48,49 were acquired. The nanopipette probe was lowered 
toward the surface at a rate of 1 μm s-1 at each position. When the surface was detected by the probe as a 
change in the phase of the AC current to a defined set point (typically 0.1° change from the bulk phase 
value), the z position was recorded and the nanopipette was retracted 5 μm at a rate of 10 μm s-1, after 
which it was moved laterally to a new location, typically 3-6 μm from the previous position. This process 
was then repeated at a minimum of 10 lateral positions, which enabled acquisition of line profile and 
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measurement of crystal height in approximately 60 seconds. Crystal dimensions were determined from 
the optical microscope images using ImageJ (version 1.45, NIH). 
 
 
Figure 1. Optical microscopy–SICM configuration. The SICM system was mounted on an inverted optical 
microscope for the simultaneous tracing of the dissolution process by optical microscopy and SICM. The 
petri dish containing the crystals was positioned on the microscope stage and the nanopipette for SICM 
scans was submerged normal to the surface. Line traces of the local height along the crystal were 
generated in hopping mode BM-SICM, with the probe scanned forward and backward over the same line 
along the crystal (right). 
 
Atomic Force Microscopy (AFM). AFM images of furosemide crystals mounted on the glass slide in the 
Petri crystallization dish were acquired in air before and after partial dissolution using a BioScope 
Catalyst microscope (Bruker, Billerica, MA). Crystals separated by >10 times the largest crystal 
dimension were allowed to dissolve partially after addition of 4 mL of 50 mM aqueous solution of KCl to 
the petri dish for 10 minutes. The electrolyte solution was then removed and the partially dissolved 
crystals were rinsed quickly with DI water and dried with a nitrogen stream. AFM images were acquired 
in the ScanAsyst mode using triangular-shaped silicon nitride cantilevers (SNL-10, Bruker, Billerica, MA) 
with a resonant frequency of ~65 kHz and ~0.35 N/m spring constant and a data collection resolution of 
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512 points per raster line. The images were analyzed with SPIP software (6.0.14, Image Metrology, 
Denmark). 
Simulations. Numerical simulations were performed using the commercial finite element method 
package Comsol Multiphysics 4.4 (Comsol AB, Sweden) installed on a Dell Intel Core 7i Quad 2.93 GHz 
computer equipped with 16 GB of RAM running Windows 7 Professional 64 bit. The “mass transport of 
diluted species” module was used in the 3D domain illustrated in Figure 2.  
 
 
Figure 2. Three-dimensional domain used for FEM simulations (not drawn to scale). The numbers 
correspond to the boundaries described in Table 1. 
The maximum characteristic diffusional time for mass transport from microscopic surfaces to bulk 
solution can be estimated using a semi-infinite diffusion model according to equation 1, where tdiff is the 
steady-state diffusion time, d is crystal largest dimension size and D denotes diffusion coefficient. 
  (1) 
The diffusion coefficient of furosemide was estimated from the Wilke-Chang correlation50 (6.15  10-6 
cm2/s) and was assumed constant over the entire domain. The diffusion time for a dissolving crystal of d ~ 
45 μm is about 3 seconds, three orders of magnitude faster than the duration of a typical crystal 
dissolution experiment (30 minutes for the complete dissolution of a crystal). The influence of convection 
was neglected due to the small nature of the studied crystals (largest dimension < 60 m).51 Mass 
transport by diffusion was therefore assumed to be effectively at a steady-state, such that the flux 
conservation relation in equation 2 was valid, where J is the flux, c is the concentration of the furosemide 
solute, and D is the furosemide diffusion coefficient.  
   (2) 
Ddtdiff /
2
02  cDJ
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The model, denoted here M1, was developed by applying a flux (per unit area) for each crystal face 
(observed dissolution rate,
Obs
hklJ )( ) measured experimentally. Using the appropriate boundary conditions 
(Table 1) the concentration of furosemide in the solution around the dissolving crystal could be simulated, 
from which it was possible to distinguish the dissolution regime, i.e., mass transport vs. kinetic control; 
vide infra. In order to deduce the relative importance of mass transport and surface kinetics, a model (M2) 
with the same geometry but different boundary conditions was employed (Table 1), such that dissolution 
was controlled by diffusion (crystal/solution interface saturated). Solution of the partial differential 
equations for both models (M1 and M2) was achieved using the direct solver MUMPS in the COMSOL 
environment, with a relative error tolerance of 10-6. Simulations were carried out with >7,500,000 
tetrahedral mesh elements. The mesh resolution was refined to be the finest, down to a value of 0.1 nm, at 
the surfaces of the crystal. 
Table 1. Boundary conditions for numerical simulations of furosemide crystal dissolution 
Boundary Characteristics 
Boundary conditions 
M1 
Boundary conditions 
M2 
1, 2 Crystal faces {010} )()( cDJ
Obs
hkl  n   
3, 4 Crystal faces {101} )()( cDJ
Obs
hkl  n   
5 Crystal face (001) )()( cDJ
Obs
hkl  n   
6, 7, 8, 9, 10 Bulk solution   
11 Glass slide   
The boundary numbers are for the planes labeled in Figure 2 
n denotes the vector normal to the surface 
cs is the solubility concentration of furosemide (0.2 mM) 
 
  
scc 
scc 
scc 
00  cc 00  cc
)(0 cD n )(0 cD n
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RESULTS AND DISCUSSION 
Furosemide crystals. Four polymorphic forms and two solvates of furosemide have been reported 
previously.37,52,53 The investigation described herein focused on Polymorph I, which is the only 
polymorph present in the commercial drug.53 Single crystal CCD X-ray diffraction confirmed that 
recrystallized furosemide crystals were polymorph I, which crystallizes in the triclinic P-1 space group 
(see Supporting Information Table S1).37 Powder X-ray diffraction of furosemide crystals grown on a 
glass slide from ethanol/water solutions supersaturated with furosemide revealed only peaks 
corresponding to the (00l) reflections (l = 1 - 3), confirming that the crystals were oriented with the (001) 
face parallel to the glass slide (Supporting Information, Figure S1). Optical microscopy revealed a raft-
like habit with a triclinic morphology (Figure 3A, B).  
 
 
 
Figure 3. Morphology of a typical recrystallized furosemide crystal (Polymorph I). The different faces that 
can be seen are labeled. (A) Image acquired with an optical microscope, normal to the (001¯) face. (B) 
Optical image acquired with a magnifying CCD camera in an SICM experiment (the lighter image is the 
reflection of the actual crystal in the glass slide). (C) Habit of furosemide Polymorph I calculated using the 
growth morphology method, viewed normal to the (001¯) face. (D) Calculated habit of furosemide 
Polymorph I oriented to reveal other major crystal faces. 
 
Crystal morphology prediction can serve as a useful aid in identifying relevant crystal faces when crystal 
dimensions are less than those required for indexing by X-ray diffraction. Methods for predicting crystal 
morphology based on crystal structure have become routine and yield crystal morphologies that are 
consistent with experimental morphologies for a wide range of molecular crystals despite a lack of 
consideration for the external growth environment.54 These methods include (i) the Bravais-Friedel 
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Donnay-Harker (BFDH), a geometric calculation based on crystal lattice and symmetry; (ii) the 
equilibrium method, based on the surface free energies of relevant crystal faces; and (iii) the growth (or 
“attachment energy”) method, based on attachment energies corresponding to relevant crystal faces. The 
growth method (iii) is most effective when considering only the internal interactions of the crystal 
structure.55-56 The growth method, developed by Hartmann and Perdok, relies on the bond energy released 
when one building unit is attached to the surface of a crystal face to predict crystal morphology.57,58 The 
growth rate normal to a particular face is proportional to the attachment energy for that surface — large 
attachment energies (i.e. more negative values) for a specific face correspond to strong out-of-plane 
intermolecular interactions, corresponding to faster growth normal to the plane and a lower morphological 
significance for the face.  
Three force fields that have been used often for the prediction of organic crystals habits59-61 were 
evaluated for predicting the morphology of furosemide Polymorph I. The molecular geometries and 
lattice parameters of the furosemide unit cell were optimized using the COMPASS, Dreiding, and cvff 
forcefields (see Supporting Information Table S2). The COMPASS forcefield was chosen for morphology 
calculations because it provided the lowest lattice energy and the lattice parameters best matched those of 
the experimental unit cell. The furosemide morphology predicted from the COMPASS forcefield reveals 
that three crystal faces — (001), (010) and (101¯) — contribute to 90% of the predicted total area of the 
crystal (Figure 3C, D; Table 2). Crystal faces with a calculated area of <5% were not observed in the 
experimental morphology, which is not surprising given that experimental crystal habit is strongly 
affected by many environmental factors, including solvent, supersaturation, pH, and temperature,59,62 
which are not captured in the morphology prediction calculations. These crystal faces, if present, cannot 
be studied by the measurements conducted in our experiments and are not addressed here. 
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Table 2. Morphology predictions for the optimized structure of furosemide (Polymorph I) by growth 
morphology calculations using COMPASS force field.  
Face (hkl) dhkl (Å) Eatt (kcal mol-1) Total facet area (%) 
(0 0 1) 13.854 -33.917 53.16 
(0 1 0) 9.021 -78.355 18.15 
(1 0 1¯) 8.613 -79.740 18.82 
(0 1 1¯) 8.469 -87.333 3.44 
(1 0 0) 8.411 -94.402 1.81 
(1 1¯ 0) 8.365 -124.774 4.02 
(1 1¯ 1¯) 7.626 -124.298 0.59 
Determination of dissolution rates and interfacial concentrations. Since the introduction of SICM,34 
different modes such as constant distance,35 hopping approach,49 and hybrid63 have been used to acquire 
images of the topography of soft surfaces36, 64 and for local ion current measurements.65-67 Most recently, a 
new method based on the application of an oscillating bias between both QRCEs to generate an 
alternating ion current (AC) feedback signal, bias modulated SICM (BM─SICM),47 has been introduced. 
This approach has several advantages over the traditional nanopipette oscillation SICM method, including 
minimization of perturbations of the local ionic atmosphere  and from effects of convection (stirring) and 
electro-osmosis. Moreover, it offers opportunities for faster imaging.67 
The dissolution rate is expected to be determined by a combination of (i) interfacial (intrinsic) dissolution 
kinetics, which are governed by energetics of the surface and solvation effects, and (ii) mass transport of 
dissolved species from the crystal surface to the bulk solution.18 Consequently, dissolution kinetics 
reflects a competition between these two processes, with the slowest governing the overall rate, leading to 
either kinetic (interfacial) control, mass transport (diffusion) control, or a mixed regime where both 
contributions are comparable. The measurement of intrinsic dissolution kinetics requires the mass 
transport rates to be comparable to or greater than surface kinetics, which in turn requires that mass 
transport is well defined and calculable.  
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The temporal change in the lateral dimensions of furosemide crystals (i.e. the size of the (001) face) was 
recorded by measurement of the retreat of the {010} and {101} faces using optical microscopy (Figure 
4A). The changes in crystal height (normal to the (001) face) were obtained by BM-SICM for the (001) 
face (Figure 4B, D). Collectively, these measurements identify the change in crystal size for all three 
dimensions. The dissolution rate was effectively constant for all three faces during the first ten minutes, 
but at longer times the dissolution rate increased. The faster dissolution rate was accompanied by surface 
roughening and the formation of pits on the (001) surface (vide infra), which were evident even in optical 
images. It is reasonable to suggest that the roughened surfaces and pits would result in higher index 
microfacets in the crystal surface, leading to enhanced dissolution kinetics (Figure 4A). Under these 
conditions, it is anticipated that crystal dissolution becomes increasingly limited by mass transport.28,68-70 
This is consistent with our recent observation of the dissolution kinetics of the (110) face of salicylic acid 
in aqueous solution using hopping intermittent contact-scanning electrochemical microscopy,70 where we 
found a strong influence of surface roughness on the dissolution kinetics. 
 
Figure 4. (A) Representative time-lapse optical microscopy images of the dissolution of a furosemide 
crystal. (B) BM-SICM line scans recorded at : 4 (■), 10 (), 15 (), 20 (), 23 () and 26 () minutes 
after the beginning of dissolution. (C) Retreat of the {010} and {101} faces (length and width dimensions) 
over time. (D) Reduction of the crystal height during dissolution, plotted as an average value of all the 
hops landed on the crystal surface in a SICM line scan. 
 13 
The early stage of dissolution, where the rate was constant, was investigated for nine furosemide crystals 
in order to compare the initial dissolution rates for the three crystallographically unique crystal faces. In 
this regime the dissolution rates likely correspond to the kinetic processes at the low index faces rather 
than the higher index microfacets that define the pitted surface. The rates of dissolution (
Obs
hklJ )( ) were 
determined using equation 3, where v(hkl) is the dissolution velocity of face hkl and Vmcrystal is the molar 
volume of furosemide (200.692 cm3/mol, calculated from the density of polymorph I, 1.648 g/cm3). The 
standard deviation of the
Obs
hklJ )(  values is rather large, which can be attributed to the small sample size, the 
use of crystals with slightly different dimensions, and mixed kinetic-mass transport control (vide infra). 
Nonetheless, it is evident that the different faces exhibit different dissolution rates, with 
Obs
hklJ )(  increasing 
in the order (001) < (010) < (101¯), inversely proportional to the areas of the faces.  
crystalmhkl
Obs
hkl VvJ /)()(   
(3) 
 
Table 3. Average face-resolved initial dissolution rates of 9 furosemide crystals. 
 
 
 
 
Crystallographically unique faces of a molecular crystal will have different chemical compositions and 
molecular topography. Consequently, different interactions with the external environment can be 
expected for these faces,71 as well as different step/kink energetics. The dissolution rates of crystal faces 
depend on the energetics associated with each surface. The lowest energy surfaces are those in which the 
weakest bonds are truncated. In the furosemide crystal, each molecule participates in six hydrogen bonds 
with five neighboring furosemide molecules — one OHO, one OHO, two NHO, and two OHN 
(Scheme 2), forming a complex hydrogen-bonding network that is truncated differently at each of the 
morphologically significant (001), (010), and (101¯) faces (Figure 5). The (001) face presents furanyl 
rings, which do not form hydrogen bonds with other furosemide molecules, to the external environment. 
Moreover, the hydrogen bonding network is contained within the (001) plane such that hydrogen bonds 
Face (hkl) JObs (mol m-2 s-1) 
(101¯) (16.1± 6.7)  10
-6 
(010) (12.6 ± 6.9)  10-6 
(001) (2.8 ± 1.4)  10-6 
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are not truncated at the surface and in-plane interactions are strong, characteristic of a face with low 
surface energy, slow growth, and a large morphological importance (Figure 5A). In contrast, the (010) 
and (101¯) surfaces expose aminosulfonyl and carboxyl groups at the surface, thereby truncating the 
hydrogen-bonding network (Figure 5B, C). Based on this structural inspection alone, the (001) face would 
be expected to have a lower attachment energy than the (010) and (101¯) faces and should have the slowest 
growth rate normal to the surface, and be the slowest dissolving crystal face as well. This is consistent 
with the observed and calculated crystal morphology (Figure 3 and Table 2), as well as the measured 
dissolution rates (Table 3). The comparable morphological significance of (010) and (101¯) suggests that 
these surfaces have comparable growth and dissolution rates. The (101¯) face, however, exhibits a 
somewhat higher dissolution rate compared to (010), although the two are comparable within error. The 
corrugation of the (010) face suggests that solvent ordering or surface reconstruction may be likely, which 
would stabilize this face and slow its dissolution rate compared to the relatively flat (101¯) face.72 
Nonetheless, the order of the observed dissolution rates of the different furosemide crystal faces (001) < 
(010) < (101¯) agrees with the hydrogen bonding model as well as the attachment energy calculations. This 
trend becomes even clearer when mass-transport corrections are introduced (vide infra). 
 
Scheme 2. The molecular structure of furosemide (black) and hydrogen bonds formed by each molecule 
with neighboring furosemide molecules (grey) in the crystal structure.  
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Figure 5. Structure of furosemide crystal faces: (A) (001), (B) (010), and (C) (101¯). Black dotted lines 
represent hydrogen bonds. 
 
Mass transport-corrected intrinsic dissolution kinetics. FEM models were formulated for each of the 
nine crystals studied to obtain more insight into the dissolution kinetics, particularly the role of mass 
transport. These computations accounted for the experimental dissolution rate (
Obs
hklJ )( ) obtained for each 
individual crystal face, crystal size and crystal morphology, thereby producing the concentration 
distribution and diffusive flux of furosemide. The results from FEM modeling of the dissolution of four 
representative furosemide crystals are provided in Figure 6. The calculations reveal that the concentration 
of furosemide at the solid/liquid interface is higher than in the bulk solution, with large concentration 
gradients (diffusion layer) between the crystal and the bulk solution, consistent with significant 
contributions from mass transport. Notably, the calculated concentration in the vicinity of each crystal 
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face differs, demonstrating that the balance between mass transport and surface kinetics for each crystal 
face during the dissolution process is different. The calculated surface concentrations increase in the order 
C(001) = 0.12 ± 0.04 mM < C(010) = 0.15 ± 0.04 mM < C(101¯) = 0.17 ± 0.03 mM, consistent with the order of 
faster kinetics expected and a trend towards an increased degree of mass transport control. The 
contribution of surface kinetics is important on those faces where the interfacial concentration is less than 
the solubility of furosemide (0.2 mM),73 a value that was confirmed by UV‒Vis absorption (Supporting 
Information, Figure S2). The interfacial concentration alone, however, is not indicative of dissolution 
kinetics due to the possible redistribution of the solute between the different crystal faces, which depends 
on the direction and magnitude of the diffusive flux of material, crystal size and morphology. A more 
accurate quantitative determination of the contribution of the surface kinetics (
SK
hklJ )( ) can be obtained for 
each crystal face by comparing the experimental flux (
Obs
hklJ )( ) determined in model M1 (see Experimental 
Section), with the value of the theoretical diffusive flux on each crystal face predicted from simulations 
for a pure mass transport controlled system (
MT
hklJ )( ) parameterized with the same crystal geometry (model 
M2). The overall flux involves mass transport and surface kinetics in series, according to equation 4,  
SK
hkl
MT
hkl
Obs
hkl JJJ )()()(
111
   
 
(4) 
Obs
hklJ )(  for (010) and (101¯) was very close to 
MT
hklJ )(  (
Obs
hklJ )(  ≈ 
MT
hklJ )( ), consistent with fast surface 
dissolution kinetics (
SK
hklJ )(  >> 
MT
hklJ )( ). Conversely, for the (001) face, except for one crystal (among the 
nine) that could not be distinguished from mass-transport control, 
Obs
hklJ )(  was always much smaller than 
MT
hklJ )(  (
Obs
hklJ )(  << 
MT
hklJ )( ), consistent with mixed kinetic control (
SK
hklJ )(  ≈ 
MT
hklJ )( ). For the (001) face, the 
average value of 
MT
hklJ )(  for the range of crystals shown (7.35  10
-6 mol m-2 s-1) is about twice the size of 
the average value of 
SK
hklJ )(  (4.39  10
-6 mol m-2 s-1). It is important to note, however, that a range in values 
was obtained for 
Obs
hklJ )(  , 
MT
hklJ )(  and 
SK
hklJ )(  across the different crystals studied. This is attributed to the 
different numbers of defects in each crystal and the different crystal sizes. The average values for each 
flux contribution for each crystal face are provided in Table 4 (more detail is provided in Supporting 
Information Table S3). 
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Figure 6. A) Optical microscopy images of single furosemide crystals. B) Results of FEM simulations 
(M1) for the concentration distribution of furosemide during the dissolution. C) Concentration distribution 
of furosemide in the solid/liquid interface in a mass transport controlled dissolution process (M2).  
Table 4. Average diffusive fluxes per unit area for each crystal face calculated from FEM simulations of 
eight furosemide crystals. 
Face (hkl) JObs (mol m-2 s-1) JMT (mol m-2 s-1) JSK (mol m-2 s-1) 
(101¯) (16.1 ± 6.7)  10
-6 (15.0 ± 4.9)  10-6 Near diffusion control 
(010) (12.6 ± 6.9)  10-6 (11.7± 3.6)  10-6 Near  diffusion control 
(001) (2.8 ± 1.4)  10-6 (7.4 ± 1.8)  10-6 (4.4 ± 2.7)  10-6 
Dislocations are recognized to be important for etch pit formation during dissolution.74 Pitting leads to 
both an increase in the specific surface area and the formation of microdomains (pit walls) of higher 
surface energy that produces an increased dissolution rate.70 In the case of furosemide crystals, a 
collection of crystals was examined by AFM before and after their immersion in aqueous solution for 10 
minutes (Figure 7). Prior to dissolution the (001) surfaces are largely free of defects, except for crystal C, 
which appears to be somewhat rough based on an AFM line profile (red line in Figure 7C). After 
simultaneous immersion for 10 minutes, the crystals have dissolved, although to different extents. 
Moreover, the number and depth of pits on the (001) face differ for each crystal. It can be appreciated in 
the images that the extent of dissolution depends on the initial crystal size, the ratio of the size of the 
(010) and (101¯) faces, and the initial surface roughness. Overall, the smaller the crystal, and the smaller 
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the size of the (101¯) face in relation to the (010) face, and the rougher the crystal surface, the faster the 
dissolution. All these characteristics are united in crystal C which is the smallest crystal (37 µm length), 
has a small (101¯) face and the clear presence of a defect on the (001) surface (surface roughness profile in 
red in Figure 7) prior to dissolution. After 10 minutes, crystal C has dissolved by ca. 70 % from its initial 
volume, while the other crystals have dissolved by between 45 % and 60 %. Differences in the pitting 
density (surface area and roughness) are evident in the images after dissolution and the surface roughness 
plot in Figure 7. The (001) surface of the dissolved crystals A and B is characterized by a smaller 
proportion of pits than crystals C and D. After the 10 minute dissolution period, the decrease in crystal 
size, as well as the roughening of the crystal faces exposed to the solvent by the formation of pits and 
exposure of high index faces, explains the increased dissolution kinetics at longer times (Figure 4).  
 
Figure 7. AFM images of single furosemide crystals before dissolution and after partial dissolution for 10 
minutes. The dashed red and black lines indicate the line profile used to measure the surface roughness 
before and after dissolution respectively (left). Surface roughness (right) of the (001) face in each of the 
four crystals before dissolution (red) and after partial dissolution (black). 
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CONCLUSIONS 
 
The dissolution kinetics of the individual faces of single furosemide crystals (polymorph I) have been 
investigated by a versatile in situ multimicroscopy approach, comprising SICM and optical microscopy 
combined with finite element method (FEM) modeling. The experimental approach allowed 3D 
visualization of crystal morphology during dissolution, from which a numerical model was developed to 
calculate the concentration distribution around the crystal and dissolution flux of furosemide at the 
solid/liquid interface. This allowed the quantitative comparison of mass transport and surface kinetics. It 
has been shown that the (001) face is strongly influenced by surface kinetics (mixed kinetic control), 
while the (010) and (101¯) faces are dominated by mass transport. Our findings have important 
consequences for the reporting of dissolution kinetics: dissolution rates vary considerably from crystal to 
crystal and are time dependent at large dissolution times (>10 minutes). This is due to the impact of a 
range of factors, including subtle effects from crystal size, shape and the apparent number of defects (pits) 
in a particular crystal, and as shown by complementary AFM measurements. By studying individual 
microscale crystals within a population, we have been able to identify kinetic distributions for individual 
faces and rationalize the results in terms of crystal structure and surface properties. The ability to obtain 
this quantitative information for individual crystal faces suggests a pathway to understanding crystal 
dissolution at the molecular level that can be used to tailor crystal morphology to enhance dose-release 
properties and regulating bioavailability. More generally, the proposed approach should be widely 
applicable to a range of crystal types, encompassing organic and ionic crystals. 
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Face-discriminating dissolution kinetics of furosemide single 
crystals: In situ three-dimensional multimicroscopy and modeling 
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We present a versatile in situ multimicroscopy approach to study the dissolution kinetics of single 
crystals. The combination of optical microscopy and scanning ion-conductance microscopy 
measurements with finite element method (FEM) modeling allows the measurement of the dissolution 
rate of all the exposed crystal faces simultaneously, determination and quantification of the limiting 
process regulating dissolution. 
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Table S1. Crystallographic parameters for furosemide Polymorph I compared with literature. 
 This study  Babu et al.*  
Empirical formula  C12H11ClN2O5S  C12H11ClN2O5S  
Formula weight  330.74  330.74  
Temperature/K  150(2)  100(2)  
Crystal system  triclinic  triclinic  
Space group  P-1  P-1  
a/Å  9.5355(5)  9.5150(9) 
b/Å  10.4627(5)  10.4476(10) 
c/Å  15.6209(7)  15.5826(16) 
α/°  92.936(4)  92.839(2) 
β/°  107.105(5)  107.088(2)  
γ/°  116.498(5)  116.7470(10) 
Volume/Å3 1302.36(10)  1291.9(2) 
Z  4  4  
ρcalc g/cm3 1.648  1.700 
m/mm-1 0.425  0.482 
Reflections collected  9208  13411 
Independent reflections  5166  5061 
Goodness-of-fit on F2 1.045  1.050 
Final R indexes [I>=2σ (I)]  R1 = 0.0502 R1 = 0.0668 
Final R indexes [all data]  wR2 = 0.1069 wR2 = 0.1258 
* Babu, N. J.; Cherukuvada, S.; Thakuria, R.; Nangia, A. Cryst. Growth Des. 2010, 
10, 1979-1989. 
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Figure S1. Calculated powder X-ray diffraction pattern of furosemide form I (black) and 
experimental (red) obtained for furosemide crystals mounted on a glass slide ( = Cu-Kα, 
0.1541 nm). The experimentally observed peaks at 2 = 6.04°, 12.15° and 18.17° correspond to 
the (001), (002) and (003) reflections of polymorph I respectively, confirming the orientation of 
the raft-like crystals parallel to the glass slide. 
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Table S2. Comparison of the optimized furosemide unit cell parameters calculated using the 
COMPASS, Dreiding and cvff force fields and the experimental data obtained by single crystal 
CCD X-ray diffraction. 
 
 
Energy 
(kcal mol-1) 
Unit cell parameters 
a (Å) b (Å) c (Å) A (º) β (º) γ (º) 
Experimental  9.5355 10.4627 15.6209 92.9360 107.1050 116.4980 
COMPASS -508.1135 9.8589 10.1926 14.7867 94.4689 106.0592 114.7914 
Dreiding -222.3405 9.7441 10.6284 15.6670 96.8028 108.2709 114.6225 
cvff -8.6023 10.3754 10.9100 15.8328 85.1591 110.7729 127.0457 
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Figure S2. UV–Vis spectra of furosemide dissolved in water at different concentrations. Black 
lines show the UV‒Vis spectra of furosemide in water at 0 mM, 0.0034 mM, 0.0068 mM, 0.014 
mM, 0.027 mM and 0.055 mM used for calibration. The red line shows the UV‒Vis spectra of a 
saturated solution of furosemide in water diluted 5 times. The inset shows the linear relationship 
between the absorbance and the concentration of furosemide at 277 nm. Black squares 
correspond to the calibration data and the red circle to the 5 times diluted saturated solution of 
furosemide in water.  
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Table S3. Diffusive fluxes per unit area for each crystal face calculated from finite element 
simulation of each studied crystal. 
Face (hkl) JObs (mol m-2s-1) JMT (mol m-2s-1) JSK (mol m-2s-1) 
(101¯) 5.2  10
-6 6.3  10-6 Close to diffusion control 
(010) 1.5  10-6 5.1  10-6 2.1  10-6 
(001) 0.6  10-6 4.1  10-6 0.7  10-6 
(101¯) 9.2  10
-6 8.9  10-6 Close to diffusion control 
(010) 7.7  10-6 7.3 x10-6 Close to diffusion control 
(001) 4.4 x10-6 5.7  10-6 Close to diffusion control 
(101¯) 13.6  10
-6 15.9  10-6 Close to diffusion control 
(010) 8.9  10-6 12.3  10-6 32.2 x10-6 
(001) 0.9  10-6 7.3  10-6 1.0  10-6 
(101¯) 14.5  10
-6 12.7  10-6 Close to diffusion control 
(010) 9.7  10-6 10.6  10-6 Close to diffusion control 
(001) 2.1  10-6 8.3  10-6 2.8  10-6 
(101¯) 20.3  10
-6 15.2  10-6 Close to diffusion control 
(010) 6.5  10-6 10.8  10-6 16.3  10-6 
(001) 3.6  10-6 7.7  10-6 6.7  10-6 
S7 
 
(101¯)  15.3  10
-6 17.3  10-6 Close to diffusion control 6 
(010) 22.2  10-6 14.3  10-6 Close to diffusion control 
(001) 3.7  10-6 8.4  10-6 6.6  10-6 
(101¯)  18.8  10
-6 16.4  10-6 Close to diffusion control 
(010) 16.6  10-6 12.0  10-6 Close to diffusion control 
(001) 2.4  10-6 6.7  10-6 3.7  10-6 
(101¯) 17.4  10
-6 19.2  10-6 Close to diffusion control 
(010) 17.9  10-6 15.5  10-6 Close to diffusion control 
(001) 2.8  10-6 6.8  10-6 4.8  10-6 
(101¯) 30.2  10
-6 23.3  10-6 Close to diffusion control 
(010) 22.4  10-6 17.0  10-6 Close to diffusion control 
(001) 4.9  10-6 11.0  10-6 8.8  10-6 
 
 
